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HEMATOPOIESIS
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic
stem/progenitor cells involves down-modulation of C/EBP
Albertus T. J. Wierenga, Hein Schepers, Malcolm A. S. Moore, Edo Vellenga, and Jan Jacob Schuringa
Previously, we demonstrated that en-
forced activation of signal transducer and
activator of transcription 5 (STAT5A) in
human cord blood (CB)–derived stem/
progenitor cells results in enhanced self-
renewal and impaired myelopoiesis. The
present study identifies C/EBP as a criti-
cal component that is down-regulated by
STAT5. Microarray and reverse transcrip-
tase–polymerase chain reaction (RT-PCR)
analysis on STAT5A1*6-transduced CD34
cells identified C/EBP as the most promi-
nently down-regulated gene. To deter-
mine the cell-biological relevance of these
observations, a 4-OHT-inducible C/EBP-ER
proteinwasco-expressedwith theSTAT5A1*6
mutant in CB CD34 cells using a retroviral
approach. Re-expression of C/EBP in
STAT5A1*6 cells resulted in a marked restora-
tionofmyelopoiesis.Theproliferativeadvan-
tage imposed on CD34 cells by STAT5A1*6
depended on the down-modulation of
C/EBP, as reintroduction of C/EBP in-
duced a quick cell-cycle arrest and the
onset of myeloid differentiation. Long-
term culture–initiating cell (LTC-IC) fre-
quencies were elevated from 0.8%  0.6%
to 7.8%  1.9% by STAT5A1*6 as com-
pared with controls, but these elevated
LTC-IC frequencies were strongly re-
duced upon re-introduction of C/EBP in
STAT5A1*6 cells, and no second cobble-
stone area–forming cells (CAFCs) could
be generated from double-transduced
cells. Enumeration of progenitors re-
vealed that the number of colony-forming
cells (CFCs) was reduced more than
20-fold when C/EBP was co-expressed
in STAT5A1*6 cells. Our data indicate that
down-modulation of C/EBP is a prerequi-
site for STAT5-induced effects on self-
renewal and myelopoiesis. (Blood. 2006;
107:4326-4333)
© 2006 by The American Society of Hematology
Introduction
Hematopoiesis is initiated in the bone marrow, where a limited
number of pluripotent hematopoietic stem cells (HSCs) give rise to
lineage-restricted progenitors that ultimately develop into mature
erythroid, myeloid, or lymphoid cells. HSCs can both self-renew as
well as differentiate, and these processes are in part regulated by
the hematopoietic microenvironment (the osteoblastic niche) and
hematopoietic growth factors that induce signal transduction.1,2
The initiation of signal transduction results in the activation of
transcription factors such as PU.1, C/EBP, GATA1, and PAX5,
which have emerged as key switches of self-renewal, differentia-
tion, and lineage determination during hematopoiesis.3
Recently, we and others have shown that activation of the
transcription factor signal transducer and activator of transcription
5 (STAT5) has profound effects on self-renewal and lineage
commitment of HSCs.4,5 Introduction of the constitutively acti-
vated mutant STAT5A1*6 into cord blood–derived CD34 cells
resulted in enhanced self-renewal and impaired myelopoiesis,
while differentiation was diverted toward an erythroid cell fate.5 In
murine cells, the absence of STAT5 signaling resulted in a profound
defect in competitive repopulation of Stat5a/b knockout cells,6,7
while introduction of activated STAT5A1*6 into murine CD34
c-KitSca-1Lin cells led to a drastic expansion of multipotential
progenitors and promoted HSC self-renewal ex vivo.4 In addition,
enforced activation of STAT5A greatly facilitated the generation of
embryonic stem (ES) cell–derived hematopoietic stem cells with
long-term self-renewal capacity in vitro that also contributed to
hematopoiesis in vivo.8,9 Besides the effects of STAT5A on
ES-derived HSC self-renewal, we also observed that myeloid
differentiation was impaired.8 Although several lines of evidence
indicate that STAT5 signaling has profound effects on hematopoi-
etic lineage-commitment decisions and HSC self-renewal, little is
known about the underlying mechanisms.
The transcription factor CCAAT enhancer binding protein-
(C/EBP) is a key regulator of granulopoiesis.10 Cebpa/ mice
have profound defects in granulocyte differentiation,11 and C/EBP
binding sites have been identified in promoters of various myeloid-
restricted genes such as the granulocyte-colony stimulating factor
(G-CSF) receptor and neutrophil elastase.12,13 It has been noted that
C/EBP is expressed at low levels in immature HSCs and is
up-regulated upon differentiation to more committed common
myeloid progenitors (CMPs) and granulocyte/monocyte progeni-
tors (GMPs), but is shut down in megakaryocyte/erythrocyte
progenitors (MEPs) or in common lymphoid progenitors (CLPs).14
These observations suggested that the C/EBP expression level
determines the self-renewal function of HSCs. Indeed, Zhang
et al15 recently demonstrated that the HSC repopulating capacity
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and self-renewal are strongly enhanced in the absence of C/EBP.
Reversibly, introduction of C/EBP in human CD34 cells resulted
in a reduced long-term culture initiating cell (LTC-IC) frequency
and facilitated granulocytic differentiation.16 It is therefore not
surprising that disturbed C/EBP signaling is often observed in
hematological disorders such as acute myeloid leukemia (AML).17,18
Here, we demonstrate that C/EBP is down-modulated by
activated STAT5A in human cord blood–derived CD34 cells.
Introduction of a 4-hydroxytamoxifen (4-OHT)–inducible
C/EBP-ER fusion protein into STAT5A1*6 CB CD34 cells
reduced the stem and progenitor cell compartment and restored
myeloid differentiation. These data indicate that down-modulation
of C/EBP expression is a critical event in the enhanced self-
renewal and impaired myelopoiesis imposed on human CD34
cells by active STAT5A.
Materials and methods
Cell culture and retroviral transductions
CD34 cells were derived from neonatal cord blood from healthy full-term
pregnancies from the obstetrics departments of the Martini Hospital and
University Medical Center in Groningen, The Netherlands, after informed
consent. The study was approved by the Ethics of the University Medical
Center Groningen, The Netherlands. For all retroviral transduction experi-
ments, the murine stem cell virus (MSCV) retroviral expression vector was
used, which contained an encephalo-myelocarditis virus (EMCV)–derived
internal ribosomal entry site (IRES2) in front of the enhanced green
fluorescent protein (EGFP) (MiGR1 vector), DsRED2 (MiDR1 vector), or
truncated neural growth factor receptor (NGF-R) (MiNR1 vector). The
STAT5A1*6 retroviral vector was described previously,5 and the C/EBP-ER
vector was constructed by inserting a C/EBP cDNA fused to the estrogen
receptor domain (a kind gift from Dr J. Mulloy, Memorial Sloan-Kettering
Cancer Center, New York, NY16) into the EcoRI site of MigR1, MiDR1, or
MiNR1. Stable PG13 high-titer retroviral producer cell lines were gener-
ated as described previously. CB CD34 cells were transduced in 3
consecutive rounds as described previously, and double transductions were
performed by mixing viral supernatants prior to transduction of target cells.
Colony-forming cell (CFC), cobblestone area forming cell
(CAFC), LTC-IC, and second CAFC assays
CFC, CAFC, and LTC-IC assays on MS5 stromal cells were performed as
described previously.19 Briefly, CFC assays were performed in 1.2%
methylcellulose containing 30% fetal calf serum (FCS), 57.2M -mercap-
toethanol, and 2 mM glutamine (StemCell Technologies, Grenoble, France),
supplemented with 20 ng/mL interleukin-3 (IL-3), 20 ng/mL IL-6, 20
ng/mL G-CSF, 20 ng/mL c-kit ligand (KL), and 6 U/mL erythropoietin
(EPO). Cells were either plated in bulk by 1000 transduced cells per plate in
triplicate or in 96-well plates with 1, 3, 9, 27, 81, or 243 cells per well.
LTC-IC assays were performed by plating transduced CB CD34 cells in
limiting dilutions in the range of 5 to 1000 cells per well on MS5 stromal
cells in 96-well plates in LTC medium ( modified minimum essential
media [MEM] supplemented with heat-inactivated 12.5% FCS; heat-
inactivated 12.5% horse serum, penicillin, and streptomycin; 200 mM
glutamine; 57.2 M -mercaptoethanol; and 1 M hydrocortisone). After 5
weeks, methylcellulose was added to the wells. Two weeks later, wells
containing CFCs were scored as positive. CAFC assays were performed as
LTC-IC assays, but now CAFCs were counted at day 10 and at week 5 by
microscopic evaluation of cocultures. Images were visualized using a Leica
DM-IL microscope (Leica Microsystems, Rijswijk, The Netherlands) and a
40  0.60 numeric aperture (NA) objective. Only phase-dark colonies
underneath the stroma were enumerated. For second CAFC assays, CAFCs
were harvested by trypsinization of adherent cell populations, sorted on the
basis of human CD45 expression (Miltenyi, Amsterdam, The Netherlands),
and replated on fresh MS5 stroma or used for analysis.
Immunoblotting, histochemistry, and cytospins
Whole cell extracts were obtained by lysing 5  105 cells in boiling
Laemmli sample buffer for 5 minutes prior to separation on 12% sodium
dodecyl sulfate (SDS)–acrylamide gels. Proteins were transferred to
nitrocellulose filters (Millipore, Etten Leur, The Netherlands) in Tris
(tris(hydroxymethyl)aminomethane)-glycine buffer at 9 volts for 1.5 hours
using a semidry electroblotter from Bio-Rad (Veenendaal, The Nether-
lands). Membranes were blocked in phosphate-buffered saline (PBS)
containing 5% nonfat milk prior to incubation with antibodies. Binding of
antibodies was detected by enhanced chemiluminescence (ECL) according
to the manufacturer’s instructions (Roche Diagnostics, Almere, The Nether-
lands). Antibodies against STAT5 (C17) and C/EBP (N19) were obtained
from Santa Cruz (Heerhugowaard, The Netherlands) and were used in
dilutions of 1:1000. May-Gru¨nwald Giemsa staining was used to analyze
cytospins. Images were visualized using an Olympus BX50 microscope
(Olympus Nederland, Zoeterwoude, The Netherlands) and a 100  1.3 NA
oil objective.
PCR analysis
For reverse transcriptase–polymerase chain reaction (RT-PCR), total RNA
was isolated from 1  106 cells using the RNeasy kit from Qiagen (Venlo,
The Netherlands) according to the manufacturer’s recommendations. Two
micrograms of RNA was reverse transcribed with M-MuLV reverse
transcriptase (Roche Diagnostics). For PCR, 2 L cDNA was amplified
using primers as indicated in the text (sequences and conditions are
available on request) in a total volume of 50 L using 2 units of Taq
polymerase (Roche Diagnostics). As a negative control, RNA minus reverse
transcriptase (RT)–prepared cDNA was used in PCR reactions. Aliquots
of 10 L were run on 1.5% agarose gels. For real-time RT-PCR, cDNA was
prepared by reverse transcribing the total RNA of 0.15  106 sorted cells
using M-MuLV reverse transcriptase (Fermentas, St Leon-Roth, Germany)
according to the manufacturer’s instructions. Aliquots (2 L) of cDNA
were then real-time amplified using iQ SYBR Green supermix (Bio-Rad)
on a MyIQ thermocycler (Bio-Rad) and quantified using MyIQ software
(Bio-Rad). HPRT (hypoxanthine phosphoribosyl-transferase) expression
was used to calculate relative expression levels.
Flow cytometry analysis
All antibodies were obtained from Becton Dickinson (Alphen a/d Rijn, The
Netherlands). Cells were incubated with antibodies at 4°C for 45 minutes.
For blocking nonspecific binding to Fc receptors, cells were blocked with
anti-Fc antibodies for 15 minutes at 4°C. All fluorescence activated cell
sorter (FACS) analyses were performed on a FACScalibur (Becton Dickin-
son), and data were analyzed using WinList 3D (Topsham, ME). Cells were
sorted on a MoFLo (DakoCytomation, Carpinteria, CA).
EMSAs
Nuclear extracts of transiently transfected 293T cells were made according
to the mini-scale procedure described by Schreiber et al.20 Electrophoretic
mobility shift assay (EMSA) analysis was performed by incubating 5 g
nuclear extract with 5-IRDye 700–labeled double-stranded oligonucleo-
tides for 30 minutes at room temperature. Binding reactions were run on
nondenaturing 4% acrylamide gels in 1 TBE (Tris/borate/EDTA), and the
gels were scanned using an Odyssey infrared scanner (Li-Cor Biosciences,
Lincoln, NE). To check for specificity of the reactions, 50-fold molar excess
of unlabeled oligonucleotide (either self or non-self) was added to the
binding reactions. For supershift analysis, 1 L C/EBP-specific antibody
(SC-61, Santa Cruz Biotechnology, Santa Cruz, CA) was added simulta-
neously with the probe.
Luciferase assays
For transactivation studies, 293T cells were transiently transfected in
12-well plates with the indicated constructs using Fugene6 (Roche, Basel,
Switzerland) according to the manufacturer’s instructions. Forty-eight
hours after transfection, cells were stimulated for 8 hours with 500 nM
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4-hydroxy tamoxifen to induce C/EBP binding, and cell extracts were made
using luciferase lysis buffer (Promega, Leiden, The Netherlands). Lucif-
erase expression was measured according to the manufacturer’s protocol
(Promega). -galactosidase expression was measured to correct for differ-
ences in transfection efficiency.
Cell-cycle analysis
Cell-cycle analysis was performed by determining the DNA content of
sorted cells by staining with 7-amino-actinomycin D in phosphate-citrate
(PC) buffer (Sigma), supplemented with 0.15 M NaCl, 5 mM EDTA
(ethylenediaminetetraacetic acid), 0.5% bovine serum albumin (BSA), and
0.02% Saponine for 10 minutes. After washing, the cells were analyzed on a
FACSCalibur flow cytometer (Becton Dickinson), and DNA profiles were
generated using Mod-Fit software (Topsham).
Results
Enforced activation of STAT5 in human CB CD34 cells results
in down-modulation of C/EBP expression
Previously, we have demonstrated that enforced activation of
STAT5A in human CB-derived CD34 stem/progenitor cells
results in enhanced self-renewal and an impairment of myeloid
differentiation.5 Affymetrix analysis of RNA isolated from MiGR1
versus STAT5A1*6-transduced cells revealed that C/EBP was the
most significantly down-modulated gene by activated STAT5A
(3.3-fold, P 	 .001). These data were confirmed by conventional
(Figure 1A) and real-time RT-PCR (Figure 2D).
To determine whether the down-modulation of C/EBP was
involved in the phenotypes that were imposed on human CB
CD34 cells by STAT5A1*6, we generated retroviral expression
vectors for C/EBP-ER. These expression vectors contained
either the truncated NGF receptor or DsRED2 as a marker gene
for the identification of transduced cells (schematically depicted
in Figure 1B). C/EBP was fused to the estrogen receptor
ligand-binding domain (ER), which allowed a 4-hydroxytamox-
ifen (4-OHT)–inducible activation of overexpressed C/EBP.
As control experiments, 293T cells were transduced with
C/EBP or C/EBP-ER, and expression was verified by West-
ern blotting (Figure 1C). The 4-OHT inducibility was tested by
C/EBP DNA-binding and transactivation assays. As shown in
Figure 1D, in the absence of 4-OHT no C/EBP DNA binding
was observed (lane 2), while stimulation of cells with 1 M
4-OHT for 1 hour resulted in the appearance of a DNA-binding
complex (lane 3) that could be outcompeted by a 50-fold excess
of unlabeled oligo (lane 4) but not by a 50-fold excess of random
unlabeled oligo (lane 5). Addition of antibody against C/EBP
resulted in the disappearance of the C/EBP-DNA complex
(Figure 1D, lane 6). As shown in Figure 1E, stimulation with 1
M 4-OHT also resulted in an increase in C/EBP transactiva-
tion. These data show that C/EBP-ER DNA binding and
transactivation were induced only in the presence of 4-OHT.
Re-expression of C/EBP in STAT5A1*6 CD34 cells results in a
restored myelopoiesis
CB-derived CD34 cells were transduced with both STAT5A1*6
and C/EBP with efficiencies of 1% to 10% of double-transduced
cells. A representative FACS plot is shown in Figure 2A (left panel)
in which an efficiency of 10% was reached. Transduced cells were
plated on MS5 stroma in the absence or presence of 4-OHT, and
hematopoietic differentiation was monitored by FACS analysis,
RT-PCRs, and cytospins. In control conditions—untransduced cells
(not shown) or C/EBP-ER without 4-OHT (Figure 2B, left
panels)—27% of the cells were positive for CD14, 31% for CD15,
65% for CD36, and 26% for CD71bright. In agreement with data
obtained previously,5,8 enforced activation of STAT5A resulted in a
block in myeloid differentiation as determined by the percentage of
cells positive for CD14 (5%) and CD15 (4%), while the number of
cells that were positive for erythroid markers was significantly
increased (85% were CD36 and 76% were CD71bright (Figure 2B,
left panels)). Re-activation of C/EBP in STAT5A1*6 cells by
administration of 1 M 4-OHT to double-transduced cells resulted
in a markedly restored myelopoiesis, as the number of CD14- and
CD15-positive cells increased from 6% to 28% and 4% to 13%,
respectively (representative data of 3 independent experiments
are shown in Figure 2B, right panels). The imposed erythroid
differentiation of CB CD34 cells by STAT5A1*6 was reversed by
reintroduction of C/EBP, as the number of CD36 and CD71bright
cells was reduced from 85% to 11% and 76% to 7%, respectively.
These results were further underscored by morphological analysis
of MiGR1, STAT5A1*6, C/EBP-ER, or double-transduced cells
(Figure 2C). Cytospins from STAT5A1*6-transduced cells con-
tained blasts, proerythroblasts, basophilic-, polychromatic-, and
orthochromatic erythroblasts as well as erythrocytes, while MiGR1
control cells differentiated mostly along the myeloid lineage as
Figure 1. Enforced activation of STAT5 in human CB CD34 cells results in
down-modulation of C/EBP expression. (A) CB-derived CD34 cells were
transduced with MiGR1 or STAT5A1*6, sorted on the basis of GFP expression, and
total RNA was isolated and used in RT-PCR reactions with primers for C/EBP and
-actin as indicated. (B) Schematic representation of the retroviral constructs that
were used in these studies. (C) C/EBP and C/EBP-ER were overexpressed in
293T cells, and total cell lysates were Western blotted using anti-C/EBP antibodies.
(D) C/EBP-ER was overexpressed in 293T cells, and nuclear extracts were used in
EMSA experiments as indicated, using a probe that contains the C/EBP consensus
binding sequence. 4-OHT induced DNA binding of C/EBP-ER, which could be
outcompeted with 50  cold self-oligo (lane 4), while DNA binding was blocked by
adding anti-C/EBP (lane 6). (E) Luciferase assays were performed in 293T cells
using luciferase reporters containing C/EBP-binding sites. Cells were transfected
with empty MiGR1 vector (control) or C/EBP-ER expression vectors, and cells were
either left unstimulated or were stimulated with 4-OHT. After 24 hours of stimulation,
cells were harvested to perform luciferase and LacZ assays as described in
“Materials and methods.”
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cytospins revealed predominantly myeloblasts, monocytes, and
granulocytes. Cytospins from C/EBP-ER–transduced cells dis-
played even more mature granulocytic development without any
signs of erythropoiesis. Double-transduced cells contained predomi-
nantly myeloblasts and monocytes. Real-time RT-PCR analyses on
sorted transduced cells revealed that constitutive activation of
STAT5A significantly down-modulated the expression of G-CSF-R
and C/EBP (Figure 2D). Reversibly, expression of C/EBP
resulted in an increase in G-CSFR expression. Also, endogenous
C/EBP expression was slightly up-regulated by C/EBP-ER as
determined by using primers that specifically recognize endoge-
nous C/EBP but not overexpressed C/EBP-ER. Reintroduction
of C/EBP-ER into STAT5A1*6 cells partly restored G-CSFR and
endogenous C/EBP expression levels. Endogenous STAT5A
expression levels were not affected by C/EBP expression (data
not shown). As controls, GFP and/or DsRED2 sorted popula-
tions were analyzed for EGFP and DsRED2 RNA levels (Figure
2D, lower panels).
Re-expression of C/EBP results in a loss of STAT5A1*6-
induced proliferative advantage of human CD34 cells
To study the proliferation of CB CD34 cells that expressed
STAT5A1*6, C/EBP, or both, transduced cells were plated on MS5
stroma, and the expansion was monitored weekly. In experiments
in which nonsorted transduced cells were used, the relative
expansion could be determined by analyzing the percentage of
GFP (STAT5A1*6), NGF-R (C-EBP-ER), or double-positive
cell populations. As shown in a representative set of experiments in
Figure 3A-C, enforced activation of STAT5A in human CB CD34
cells resulted in a proliferative advantage over MiGR1 control cells
when expanded on MS5 stroma, as the percentage of GFP cells
increased from 20% to more than 70% within 2 to 3 weeks (Figure
3A). In contrast, overexpression of C/EBP-ER resulted in a
proliferative disadvantage on MS5 stroma, as the percentage of
NGF-R cells decreased from 18% to 2% within 3 weeks (Figure
3A). In Figure 3B, the absolute cell counts of individual cocultures
are shown, and these experiments clearly indicate that expression
of activated STAT5A1*6 results in enhanced expansion on MS5
stroma, while expression of C/EBP represses the expansion on
MS5 compared with controls. When C/EBPwas reintroduced into
STAT5A1*6 cells, the proliferative advantage imposed on cells by
activated STAT5A was completely reduced to below control levels
(Figure 3B). Representative FACS profiles are shown in Figure 2A
in which treatment of 4-OHT for 1 week resulted in a decrease of
double-transduced cells from 10% to 2%. Data from 3 independent
experiments are summarized in Figure 3C, in which the relative
expansions of all groups are given compared to MiGR1 control
cells, which was set to 1 at each time point. To further confirm that
STAT5A1*6-induced proliferation depends on the down-modulation
of C/EBP, 4-OHT was administered to transduced cells at various
time points. Data in Figure 3D-E is presented as the percentage of
untransduced, STAT5A1*6 (EGFP), C/EBP-ER (NGF-R), or
double-transduced cells within 1 batch of transduced cells that was
expanded on MS5 over a 2-week period. 4-OHT was added from
Figure 2. Re-expression of C/EBP in STAT5A1*6 CD34 cells results in a restored myelopoiesis. (A) Human CB CD34 cells were transduced with
STAT5A1*6-IRES2-EGFP and C/EBP-ER-IRES2-NGF-R retroviral vectors. Representative transduction efficiencies are shown of cells grown for 1 week on MS5 stroma in the
absence (left panel) or presence (right panel) of 4-OHT. (B) Cells shown in panel A were analyzed by FACS for the expression of CD14, CD15, CD36, and CD71 expression
using allophycocyanin (APC)–conjugated antibodies. Data are representative of at least 3 independent experiments. (C) CB CD34 cells were transduced with MiGR1/NGF-R
empty vectors or double transduced with STAT5A1*6 and C/EBPa-ER, cocultured on MS5 for 1 week in the presence of 4-OHT, after which MiGR1 cells, STAT5A1*6 cells,
C/EBPa-ER cells, and double-positive cells were sorted on the MoFlo and analyzed by cytospins and May-Gru¨nwald Giemsa staining. (D) Experiment performed as described
in panel C, but total RNA was isolated after MoFlo sorting for qRT-PCR analysis as indicated. The sorted cells for data in panels C and D were obtained from gates R2, R4, and
R3, which represent C/EBP-ER, STAT5A1*6, and double-transduced cells, respectively. Double-transduced empty control cells were sorted separately (data not shown).
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the start of the experiment (Figure 3D) or at day 3 (Figure 3E), and
only when 4-OHT was administered was the proliferative advan-
tage of STAT5A1*6/C-EBP-ER over controls reduced. Taken
together, these data indicate that down-modulation of C/EBP is a
critical event for the enhancing effects of STAT5A1*6 on
proliferation.
These data were further underscored in cell-cycle experiments
of MiGR1/NGF-R and STAT5A1*6/C-EBP-ER cells in the ab-
sence or presence of 4-OHT. Enforced activation of STAT5A
resulted in an increase of the percentage of cells in S/G2/M phase
from 32% to 60%, while the percentage of cells in G1 was reduced
from 66% to 35% (Figure 3F). After 24 hours of treatment with
4-OHT, the percentage of cells in G1 was 44%, and the percentage
of cells in S/G2/M was 51%. In a separate experiment, STAT5A1*6/
C-EBP-ER cells were treated with 4-OHT for 48 hours, which
resulted in an even stronger decrease in the percentage of cells in
S/G2/M phase (Figure 3G). No increase in apoptosis was observed
upon stimulation with 4-OHT throughout all experiments (Figure
3F-G and data not shown), suggesting that the reduced expansion
upon re-expression of C/EBP into STAT5A1*6 cells does not
involve elevated apoptosis.
Expression of C/EBP results in a loss of STAT5A1*6-induced
self-renewal and long-term expansion
To enumerate the number of progenitors in transduced CB CD34
cells, STAT5A1*6, C/EBP-ER, or double-transduced cells were
sorted and plated in methylcellulose under limiting dilution condi-
tions in the absence or presence of 4-OHT. Administration of
4-OHT to MiGR1 or STAT5A1*6 cells did not affect the number of
progenitors significantly (data not shown), although expression of
STAT5A1*6 induced a shift toward significantly more erythroid
burst-forming units (BFU-Es) at the expense of granulocyte
macrophage colony-forming units (CFU-GMs) (Figure 4B). Rein-
troduction of C/EBP into STAT5A1*6 cells by stimulation with
4-OHT significantly reduced the number of progenitors. To obtain
50% positive wells, 7.6 cells in the absence of 4-OHT and 176 cells
in the presence of 4-OHT needed to be plated, resulting in a
difference in CFC formation of 23.2-fold (Figure 4A). Also, the
shift toward more BFU-E–type colonies induced by activated STAT5A
was reversed to a normal CFU-GM versus BFU-E distribution when
C/EBPwas reintroduced in STAT5A1*6 cells (Figure 4B).
The number of hematopoietic stem cells was enumerated by
CAFC and LTC-IC assays on MS5 stroma under limiting dilution
conditions. As shown in Figure 4C, enforced activation of
STAT5A1*6 resulted in the appearance of early CAFCs within 10
days after plating at a frequency of 8.2%. These early CAFCs were
not observed when C/EBP-ER was co-expressed in STAT5A1*6
cells (Figure 4C). Representative examples of cocultures at week 1
are shown in Figure 4D. After 5 weeks, methylcellulose was added
to the wells to determine the LTC-IC frequencies. Enumeration of
week 5 LTC-IC frequencies revealed that STAT5A1*6 enhanced the
frequency from 0.8% 
 0.6% to 7.8% 
 1.9% compared with
MiGR1 control cells. Importantly, this elevated LTC-IC frequency
required the down-modulation of C/EBP, as reintroduction of
C/EBP-ER in STAT5A1*6 cells significantly reduced the LTC-IC
frequency to 0.7% 
 0.5% at week 5 (Figure 4C-D). While the
STAT5A1*6 week 5 CAFCs could be harvested and passaged onto
new MS5 to generate second CAFCs, no long-term cultures could
be established from the double-transduced cells in the presence of
4-OHT (data not shown).
Figure 3. Re-expression of C/EBP results in a loss
of STAT5A1*6-induced proliferative advantage of hu-
man CD34 cells. (A) Human CB CD34 cells were
transduced with MiGR1, STAT5A1*6-IRES2-EGFP,
C/EBP-ER-IRES2-NGF-R, or both STAT5A1*6 and
C/EBP-ER, as indicated. Cells were plated on MS5
stroma in the presence of 4-OHT, and the proliferation
was monitored weekly by FACS analysis for GFP or
NGF-R. (B) Experiment performed as described in panel
A, but cells were sorted after transduction, and expansion
was monitored by determining the cell counts weekly. (C)
Combined data of 3 representative experiments in which
the relative expansion is indicated as compared to the
MiGR1 control that was set to 1 at each time point.
Significant differences were determined using a Student t
test. (D-E) Experiments as in panel B, but now 4-OHT
was added at day 0 (D) or day 3 (E). Cultures were
monitored for 14 days. Data are presented as the
percentage of untransduced, STAT5A1*6 (EGFP),
C/EBP-ER (NGF-R), or double-transduced cells within
1 batch of transduced cells that was expanded on MS5
over a 2-week period. (F) Cells were transduced as
indicated, plated onto MS5 stroma to allow expansion for
7 days, after which 4-OHT was added for an additional 24
hours. After 4-OHT stimulation, the cell-cycle distribution
was determined by FACS. (G) Experiment as in panel F,
but now cells were treated with 4-OHT for 48 hours.
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Discussion
The results presented in this manuscript allow us to reach 3 main
conclusions. First, enforced activation of the transcription factor
STAT5A in human CD34 cells results in a down-modulation of
C/EBP. Second, STAT5A1*6-induced self-renewal and long-term
expansion of human stem/progenitor cells on stroma requires the
down-modulation of C/EBP. Finally, the impaired myelopoiesis
and the bias toward erythropoiesis that is imposed upon human
CD34 cells by activated STAT5A also involves down-modulation
of C/EBP.
So far, little information is available on the molecular mecha-
nisms that are involved in self-renewal of normal and leukemic
stem/progenitor cells. Our previous studies have indicated that
activating mutations in the tyrosine kinase receptor FLT321 and
particularly enforced activation of STAT5 result in enhanced
long-term self-renewal of early stem/progenitor cells.5 Affymetrix
microarray analysis revealed C/EBP as one of the most prominent
down-regulated genes in human CB-derived CD34 cells trans-
duced with activated STAT5A1*6 or the FLT3-W51 internal tandem
duplication (Schuringa et al5 and Ki Young Chung, Giovanni
Morrone, J.J.S., and M.A.S.M., unpublished observations, June
2003). Hematopoietic stem cell self-renewal, repopulating capac-
ity, and myeloid differentiation have been closely linked to
C/EBP expression. In mouse models, loss of C/EBP in the HSC
resulted in elevated competitive reconstitution activity, while the
transition from the common myeloid progenitor to the granulocyte/
monocyte progenitor was blocked.15 Also, in mouse models,
C/EBP deficiency22 as well as dominant-negative mutations in
C/EBP23 have been shown to increase the capacity of myeloid
progenitors to proliferate. Reversibly, overexpression of C/EBP
has been associated with cell-cycle arrest and the onset of myeloid
differentiation.16,24-26 Our data indicate that the down-modulation
of C/EBP expression is a key event in the STAT5A-mediated
long-term self-renewal and impaired myeloid differentiation of
human CB-derived CD34 cells.
Our analyses at the stem and progenitor levels revealed that
introduction of an activated mutant of STAT5A, STAT5A1*6,27
resulted in the formation of early CAFCs with elevated frequencies
compared with controls (Figure 4C and Schuringa et al5). These
early CAFCs persisted for more than 5 weeks and could be
passaged onto new stroma to give rise to second and third CAFCs
for up to a period of 18 weeks. It has been shown that these CAFCs
are a representation of the number of in vivo long-term repopulat-
ing HSCs as measured in the NOD-SCID transplantation mod-
el.5,28,29 These effects of active STAT5A on human stem and
progenitor cells can be reversed by overexpression of C/EBP.
Both in LTC-IC assays as well as in CFC assays in methylcellulose
we consistently observed a distinct reduction in stem and progeni-
tor frequency, and no long-term cultures could be established from
STAT5A1*6 cells when C/EBP was re-introduced. It has been
demonstrated that in C/EBP-deficient murine HSCs Bmi-1 expres-
sion is elevated, suggesting that one of the normal functions of
C/EBPmight be to inhibit HSC self-renewal by down-modulating
Bmi-1.15 Future studies will be aimed at elucidating whether Bmi-1
expression and function is altered in human CD34 cells that
express activated STAT5A.
Our observations at the stem/progenitor level correlate with
data from hematopoietic differentiation and expansion studies.
Overexpression of C/EBP in human CD34 cells resulted in a
block in proliferation and enhanced myeloid differentiation. While
expression of activated STAT5A1*6 in CB CD34 cells resulted in a
proliferative advantage compared with control cells, this was
dramatically down-modulated by reintroduction of C/EBP. These
observations coincided with an increased percentage of cells in
S/G2/M phase when STAT5A was activated in CB CD34 cells,
which could be reduced by re-expression of C/EBP. These data
clearly indicate that down-modulation of C/EBP is required for
the proliferative advantage imposed on human CB CD34 cells by
activated STAT5A. C/EBP has been identified as a potent
suppressor of cell proliferation, and several mechanisms have been
proposed. C/EBP interacts with and inhibits cdk2/4,30 induces
expression of the cell-cycle inhibitor p21WAF-1,31 and represses
the E2F complex of cell-cycle regulatory transcription factors.32
Thus, one or more of these mechanisms could account for the
STAT5A1*6-induced proliferative advantage of human CB CD34
cells by down-modulation of C/EBP, thereby alleviating the
Figure 4. Expression of C/EBP results in a loss of
STAT5A1*6-induced self-renewal and long-term expan-
sion. (A) Human CB CD34 cells were transduced with
both STAT5A1*6-IRES2-EGFP and C/EBP-ER-IRES2-
NGF-R, and cells in gate R3 were sorted on the MoFlo.
Cells were plated in the presence or absence of 4-OHT in
methylcellulose assays in 96-well plates in limiting dilu-
tions of 1, 3, 9, 27, 81, and 243 cells per well. Two weeks
later, CFC counts were scored. (B) Cells were trans-
duced with both MiGR1/NGF-R empty vectors or
STAT5A1*6-IRES2-EGFP and C/EBP-ER-IRES2-NGF-R
as indicated. Cells were sorted and plated in bulk methyl-
cellulose cultures, and the ratio between BFU-E and
CFU-GM type colonies is shown in the absence or
presence of 4-OHT. (C) Experiment performed as de-
scribed in panel B, but sorted cells were plated onto MS5
stroma in 96-well plates in limiting dilutions of 5 to 1000
cells per well. After 5 weeks, methylcellulose was added
to the wells, and 2 weeks later wells were scored as
positive or negative to determine LTC-IC frequencies.
Data from a representative experiment are shown. (D)
Representative microscopy images of several MS5 cocul-
tures at weeks 1 and 5.
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block on cell-cycle progression. Furthermore, C/EBP has been
recognized as a key transcription factor that determines lineage
commitment from the HSC toward the GM progenitor.15 We
observed that enforced activation of STAT5A in human CD34
cells resulted in a potent block in myeloid differentiation and
diverted differentiation toward erythropoiesis. These lineage fate
decisions induced by STAT5 could be reprogrammed by re-
introduction of C/EBP into STAT5A1*6 cells.
Various lines of evidence suggest that activation of STAT5A is a
critical event in leukemic transformation. Constitutive activation of
STAT5A has been observed in the majority of acute and chronic
leukemias. A number of genetic abnormalities, such as Bcr-Abl,33,34
Tel-Jak2,35 and FLT3-ITDs36,37 induce constitutive activation of
STAT5, and particularly in the case of Tel-Jak2 it has been
demonstrated that STAT5 is necessary for Tel-Jak2–induced myelo-
proliferative disease.35 Mutations in JAK2 that result in hyperacti-
vation of STAT5 have been identified in polycythemia vera.38-41
More recently, a single activating mutation in STAT5A (cS5F) has
been shown to induce multilineage leukemia in mice.42 Neverthe-
less, no cell biological mechanisms have been identified by which
STAT5A might induce leukemic transformation of human cells.
Our data are the first to link STAT5 signal transduction to C/EBP
expression in STAT5A-mediated long-term expansion of human
hematopoietic stem/progenitor cells. Also, the disturbed myelopoi-
esis that is induced by activated STAT5A requires down-
modulation of C/EBP. It is intriguing that these phenotypes
directly parallel those observed in AML patients. Deregulation of
C/EBP expression has been observed in a variety of hematologi-
cal malignancies, including in AMLs with t(8;21),43 inv16,44 or Flt3
mutations.45 In addition, mutations in C/EBP have been identified
that either affect the transactivation potential or block the transla-
tion of the full-length 42-kDa form (p42), which leads to overex-
pression of the shorter 30-kDa form (p30) that acts as a
dominant-negative transcription factor.17,18,46 Further studies
will define whether re-introduction of C/EBP in these AML
cells will restore the differentiation process of the affected cells
only or whether it will also restrict self-renewal capacity of the
leukemic stem cell pool.
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